Skip to Main Content

Author Details

Houtan Noushmehr
Henry Ford Hospital
2003
71
36
PMIDPaper TitleJournal TitlePublished Year
37329568Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas.Neuro Oncol2023
37704607Detection of diagnostic and prognostic methylation-based signatures in liquid biopsy specimens from patients with meningiomas.Nat Commun2023
37343523Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomas.Cell Rep Med2023
37338006Targeted sequencing of cancer-related genes reveals a recurrent TOP2A variant which affects DNA binding and coincides with global transcriptional changes in glioblastoma.Int J Cancer2023
37329568Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas.Neuro Oncol2023
37432624Advances in Central Nervous System Tumor Classification.Adv Exp Med Biol2023
37704607Detection of diagnostic and prognostic methylation-based signatures in liquid biopsy specimens from patients with meningiomas.Nat Commun2023
37343523Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomas.Cell Rep Med2023
37338006Targeted sequencing of cancer-related genes reveals a recurrent TOP2A variant which affects DNA binding and coincides with global transcriptional changes in glioblastoma.Int J Cancer2023
37432624Advances in Central Nervous System Tumor Classification.Adv Exp Med Biol2023
35212383Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors.Neuro Oncol2022
35815721Molecular landscape of IDH-wild type, pTERT-wild type adult glioblastomas.Brain Pathol2022
36069696Neurosurgery's Impact on Neuro-Oncology-"Can We Do Better?"-Lessons Learned Over 50 Years.Neurosurgery2022
36380869Unmet need for liquid biomarkers and the Brain-Liquid Biopsy Consortium.Neurooncol Adv2022
36380867Noninvasive approaches to detect methylation-based markers to monitor gliomas.Neurooncol Adv2022
35212383Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors.Neuro Oncol2022
35815721Molecular landscape of IDH-wild type, pTERT-wild type adult glioblastomas.Brain Pathol2022
36069696Neurosurgery's Impact on Neuro-Oncology-"Can We Do Better?"-Lessons Learned Over 50 Years.Neurosurgery2022
36380869Unmet need for liquid biomarkers and the Brain-Liquid Biopsy Consortium.Neurooncol Adv2022
36380867Noninvasive approaches to detect methylation-based markers to monitor gliomas.Neurooncol Adv2022
33914057Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.Neuro Oncol2021
33914057Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.Neuro Oncol2021
33859362Correction to: Molecular landscape of IDH-mutant primary astrocytoma Grade IV/Glioblastomas.Mod Pathol2021
33692446Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas.Mod Pathol2021
33631002DNA methylation-based signatures classify sporadic pituitary tumors according to clinicopathological features.Neuro Oncol2021
33560371A serum-based DNA methylation assay provides accurate detection of glioma.Neuro Oncol2021
33926464Expression and regulatory roles of lncRNAs in G-CIMP-low vs G-CIMP-high Glioma: an in-silico analysis.J Transl Med2021
33926464Expression and regulatory roles of lncRNAs in G-CIMP-low vs G-CIMP-high Glioma: an in-silico analysis.J Transl Med2021
33560371A serum-based DNA methylation assay provides accurate detection of glioma.Neuro Oncol2021
33692446Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas.Mod Pathol2021
33859362Correction to: Molecular landscape of IDH-mutant primary astrocytoma Grade IV/Glioblastomas.Mod Pathol2021
33631002DNA methylation-based signatures classify sporadic pituitary tumors according to clinicopathological features.Neuro Oncol2021
31585122Mutated CEACAMs Disrupt Transforming Growth Factor Beta Signaling and Alter the Intestinal Microbiome to Promote Colorectal Carcinogenesis.Gastroenterology2020
31900418Interpreting pathways to discover cancer driver genes with Moonlight.Nat Commun2020
32127355Targeting the E3 Ubiquitin Ligase PJA1 Enhances Tumor-Suppressing TGFβ Signaling.Cancer Res2020
31585122Mutated CEACAMs Disrupt Transforming Growth Factor Beta Signaling and Alter the Intestinal Microbiome to Promote Colorectal Carcinogenesis.Gastroenterology2020
31665443Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomas.Neuro Oncol2020
33009951Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology.Acta Neuropathol2020
33162926Machine Learning Applications in the Neuro ICU: A Solution to Big Data Mayhem?Front Neurol2020
31900418Interpreting pathways to discover cancer driver genes with Moonlight.Nat Commun2020
31665443Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomas.Neuro Oncol2020
33162926Machine Learning Applications in the Neuro ICU: A Solution to Big Data Mayhem?Front Neurol2020
33009951Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology.Acta Neuropathol2020
32127355Targeting the E3 Ubiquitin Ligase PJA1 Enhances Tumor-Suppressing TGFβ Signaling.Cancer Res2020
30364927ELMER v.2: an R/Bioconductor package to reconstruct gene regulatory networks from DNA methylation and transcriptome profiles.Bioinformatics2019
31748746Longitudinal molecular trajectories of diffuse glioma in adults.Nature2019
31825847A Study of High-Grade Serous Ovarian Cancer Origins Implicates the SOX18 Transcription Factor in Tumor Development.Cell Rep2019
31667475Identification of subsets of <i>IDH</i>-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks.Neurooncol Adv2019
30487138Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus.Cancer Res2019
30131588A non-functional galanin receptor-2 in a multiple sclerosis patient.Pharmacogenomics J2019
  • 1 - 50 of 142

Recommended Authors

Daniel H??bschmann
Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM)
Career Start Year 2016
Number of shared co-authors 10
Paul Guilhamon
The Hospital for Sick Children
Career Start Year 2013
Number of shared co-authors 6
Michael Bockmayr
Institute of Pathology, Charite Universitatsmedizin Berlin
Career Start Year 2013
Number of shared co-authors 1
Natalie J??ger
Hopp Children's Cancer Center Heidelberg (KiTZ)
Career Start Year 2010
Number of shared co-authors 22
Qianghu Wang
Center for Global Health, School of Public Health, Nanjing Medical University
Career Start Year 2009
Number of shared co-authors 29
Brandy Klotzle
Departments of Bioinformatics and Clinical Genomics, Illumina Inc.
Career Start Year 2009
Number of shared co-authors 8
Lukas Chavez
University of California San Diego
Career Start Year 2008
Number of shared co-authors 13
Ritu Roy
University of California San Francisco.
Career Start Year 2007
Number of shared co-authors 6
Eunjee Lee
Chungnam National University
Career Start Year 2007
Number of shared co-authors 3
Matti Nykter
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 2006
Number of shared co-authors 16
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 33
Yassen Assenov
German Cancer Research Center (DKFZ)
Career Start Year 2006
Number of shared co-authors 4
Brock C Christensen
Geisel School of Medicine, Dartmouth College
Career Start Year 2005
Number of shared co-authors 16
Joshy George
Peter MacCallum Cancer Centre
Career Start Year 2005
Number of shared co-authors 54
Matthias Schlesner
University of Augsburg
Career Start Year 2004
Number of shared co-authors 23
Jianmin Wang
Roswell Park Comprehensive Cancer Center
Career Start Year 2003
Number of shared co-authors 3
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 23
Olivier Harismendy
University of California
Career Start Year 2003
Number of shared co-authors 3
Syed Haider
Institute of Cancer Research
Career Start Year 2002
Number of shared co-authors 26
Michael Slifker
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 0
Olivier Elemento
Meyer Cancer Center
Career Start Year 2002
Number of shared co-authors 33
Yidong Chen
The University of Texas Health Science Center at San Antonio
Career Start Year 2001
Number of shared co-authors 8
Vladimir Makarov
Center for Immunotherapy and Precision-Immuno-Oncology, Cleveland Clinic
Career Start Year 2001
Number of shared co-authors 11
Mikhail G Dozmorov
Virginia Commonwealth University
Career Start Year 2001
Number of shared co-authors 2
Yan W Asmann
Mayo Clinic
Career Start Year 2000
Number of shared co-authors 27
Hugues Sicotte
Mayo Clinic
Career Start Year 1999
Number of shared co-authors 50
Benedikt Brors
German Cancer Research Center (DKFZ)
Career Start Year 1997
Number of shared co-authors 21
John V Pearson
QIMR Berghofer Medical Research Institute
Career Start Year 1996
Number of shared co-authors 37
Luigi Marchionni
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 5
Paul C Boutros
University of California los angeles
Career Start Year 1970
Number of shared co-authors 57

Collaborators

Tathiane M Malta
School of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo
Co-authored papers 22
Thais S Sabedot
Co-authored papers 15
Simon G Coetzee
Co-authored papers 13
Gerhard A Coetzee
Van Andel Institute
Co-authored papers 12
Simon A Gayther
Cedars-Sinai Medical Center
Co-authored papers 11
Laila M Poisson
Co-authored papers 11
Peter W Laird
Van Andel Institute
Co-authored papers 10
Tom Mikkelsen
Ontario Brain Institute
Co-authored papers 8
Jill S Barnholtz-Sloan
National Cancer Institute
Co-authored papers 8
Beth Y Karlan
David Geffen School of Medicine, University of California los angeles
Co-authored papers 8
Kenneth Aldape
National Cancer Institute
Co-authored papers 7
Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 7
Tiago C Silva
University of Miami Miller School of Medicine
Co-authored papers 7
Roel G W Verhaak
Yale School of Medicine
Co-authored papers 6
Antonio Colaprico
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine
Co-authored papers 6
Benjamin P Berman
Institute for Medical Research Israel-Canada, The Hebrew University of Jerusalem
Co-authored papers 6
Hui Shen
Van Andel Institute
Co-authored papers 6
Alvaro N A Monteiro
H. Lee Moffitt Cancer Center & Research Institute
Co-authored papers 6
Jonathan Tyrer
Co-authored papers 6
Georgia Chenevix-Trench
QIMR Berghofer Medical Research Institute
Co-authored papers 6
Daniel J Weisenberger
Co-authored papers 6
Susan J Ramus
School of Clinical Medicine, University of NSW Sydney, Lowy Cancer Research Centre
Co-authored papers 6
Matthew L Freedman
Dana-Farber Cancer Institute
Co-authored papers 6
Antonio Iavarone
Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami
Co-authored papers 6
Suhn K Rhie
Keck School of Medicine of USC
Co-authored papers 5
David Van Den Berg
Co-authored papers 5
Tanja Pejovic
Oregon Health & Science University
Co-authored papers 5
Ho-Keung Ng
Chinese University of Hong Kong
Co-authored papers 5
Andrew E Sloan
Co-authored papers 5
Ellen L Goode
Mayo Clinic College of Medicine
Co-authored papers 5
Release 1.2